Literature DB >> 11156321

Loss of MHC class II expression is associated with a decrease of tumor-infiltrating T cells and an increase of metastatic potential of colorectal cancer: immunohistological and histopathological analyses as compared with normal colonic mucosa and adenomas.

M Warabi1, M Kitagawa, K Hirokawa.   

Abstract

We immunohistologically investigated 76 cases of primary colorectal cancer and 13 cases of adenoma to clarify the relationship of MHC class II expression with the grade of differentiation, the density of tumor-infiltrating lymphocytes, and the incidence of metastasis to lymph nodes. MHC class II expression was mostly negative in normal colonic epithelium. In contrast, 32 out of 76 cases (42%) of cancer and five out of 13 cases (38%) of adenoma were positive for MHC class II. MHC class II expression was higher in well-differentiated than in poorly differentiated adenocarcinoma. The density of infiltrating lymphocytes was higher in cancer than in the normal mucosa, and higher in MHC class II-positive tissues than in negative lesions. The incidences of lymphatic invasion and cancer metastasis to lymph nodes were definitely higher in MHC class II-negative cancers than in MHC class II-positive cancers. MHC class II was rarely expressed in metastatic cancer cells of lymph nodes. These results indicated that the loss of MHC class II is correlated with the incidence of metastasis to regional lymph nodes.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11156321     DOI: 10.1016/S0344-0338(00)80080-1

Source DB:  PubMed          Journal:  Pathol Res Pract        ISSN: 0344-0338            Impact factor:   3.250


  20 in total

1.  Histone Deacetylase Inhibition Sensitizes PD1 Blockade-Resistant B-cell Lymphomas.

Authors:  Xiaoguang Wang; Brittany C Waschke; Rachel A Woolaver; Zhangguo Chen; Gan Zhang; Anthony D Piscopio; Xuedong Liu; Jing H Wang
Journal:  Cancer Immunol Res       Date:  2019-06-24       Impact factor: 11.151

Review 2.  Rebalancing immune specificity and function in cancer by T-cell receptor gene therapy.

Authors:  Akshata Udyavar; Terrence L Geiger
Journal:  Arch Immunol Ther Exp (Warsz)       Date:  2010-08-01       Impact factor: 4.291

Review 3.  Targeting A2 adenosine receptors in cancer.

Authors:  David Allard; Martin Turcotte; John Stagg
Journal:  Immunol Cell Biol       Date:  2017-02-08       Impact factor: 5.126

4.  Identification of novel compounds that enhance colon cancer cell sensitivity to inflammatory apoptotic ligands.

Authors:  Avijeet S Chopra; Anton Kuratnik; Eric W Scocchera; Dennis L Wright; Charles Giardina
Journal:  Cancer Biol Ther       Date:  2013-02-01       Impact factor: 4.742

5.  Low GILT Expression is Associated with Poor Patient Survival in Diffuse Large B-Cell Lymphoma.

Authors:  Hannah Phipps-Yonas; Haiyan Cui; Noemi Sebastiao; Patrick S Brunhoeber; Ellen Haddock; Martin J Deymier; Wolfram Klapper; Lonnie Lybarger; Denise J Roe; Karen Taraszka Hastings
Journal:  Front Immunol       Date:  2013-12-04       Impact factor: 7.561

6.  Fas ligand expression in lynch syndrome-associated colorectal tumours.

Authors:  Jan J Koornstra; Steven de Jong; Wietske Boersma-van Eck; Nynke Zwart; Harry Hollema; Elisabeth G E de Vries; Jan H Kleibeuker
Journal:  Pathol Oncol Res       Date:  2009-09       Impact factor: 3.201

7.  Dysregulated recruitment of the histone methyltransferase EZH2 to the class II transactivator (CIITA) promoter IV in breast cancer cells.

Authors:  Agnieszka D Truax; Meghna Thakkar; Susanna F Greer
Journal:  PLoS One       Date:  2012-04-26       Impact factor: 3.240

Review 8.  HLA class I loss in colorectal cancer: implications for immune escape and immunotherapy.

Authors:  Per Anderson; Natalia Aptsiauri; Francisco Ruiz-Cabello; Federico Garrido
Journal:  Cell Mol Immunol       Date:  2021-01-20       Impact factor: 22.096

9.  Activation of ERα signaling differentially modulates IFN-γ induced HLA-class II expression in breast cancer cells.

Authors:  Ahmed A Mostafa; Dianne Codner; Kensuke Hirasawa; Yumiko Komatsu; Matthew N Young; Viktor Steimle; Sheila Drover
Journal:  PLoS One       Date:  2014-01-27       Impact factor: 3.240

10.  Melanoma-specific MHC-II expression represents a tumour-autonomous phenotype and predicts response to anti-PD-1/PD-L1 therapy.

Authors:  Douglas B Johnson; Monica V Estrada; Roberto Salgado; Violeta Sanchez; Deon B Doxie; Susan R Opalenik; Anna E Vilgelm; Emily Feld; Adam S Johnson; Allison R Greenplate; Melinda E Sanders; Christine M Lovly; Dennie T Frederick; Mark C Kelley; Ann Richmond; Jonathan M Irish; Yu Shyr; Ryan J Sullivan; Igor Puzanov; Jeffrey A Sosman; Justin M Balko
Journal:  Nat Commun       Date:  2016-01-29       Impact factor: 14.919

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.